- Home
- FGEN vs ELEV Comparison
FGEN vs ELEV Comparison
Compare FGEN & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- ELEV
- Stock Information
- Founded
- FGEN 1993
- ELEV 2019
- Country
- FGEN United States
- ELEV United States
- Employees
- FGEN N/A
- ELEV N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- FGEN Health Care
- ELEV Health Care
- Exchange
- FGEN Nasdaq
- ELEV Nasdaq
- Market Cap
- FGEN 34.5M
- ELEV 37.6M
- IPO Year
- FGEN 2014
- ELEV 2021
- Fundamental
- Price
- FGEN $0.36
- ELEV $0.64
- Analyst Decision
- FGEN
- ELEV Strong Buy
- Analyst Count
- FGEN 0
- ELEV 5
- Target Price
- FGEN N/A
- ELEV $7.20
- AVG Volume (30 Days)
- FGEN 911.8K
- ELEV 716.1K
- Earning Date
- FGEN 11-12-2024
- ELEV 11-06-2024
- Dividend Yield
- FGEN N/A
- ELEV N/A
- EPS Growth
- FGEN N/A
- ELEV N/A
- EPS
- FGEN N/A
- ELEV N/A
- Revenue
- FGEN $180,015,000.00
- ELEV N/A
- Revenue This Year
- FGEN $19.67
- ELEV N/A
- Revenue Next Year
- FGEN N/A
- ELEV N/A
- P/E Ratio
- FGEN N/A
- ELEV N/A
- Revenue Growth
- FGEN 16.15
- ELEV N/A
- 52 Week Low
- FGEN $0.18
- ELEV $0.44
- 52 Week High
- FGEN $2.93
- ELEV $5.83
- Technical
- Relative Strength Index (RSI)
- FGEN 45.24
- ELEV 57.75
- Support Level
- FGEN $0.31
- ELEV $0.61
- Resistance Level
- FGEN $0.37
- ELEV $0.70
- Average True Range (ATR)
- FGEN 0.03
- ELEV 0.07
- MACD
- FGEN -0.01
- ELEV 0.00
- Stochastic Oscillator
- FGEN 25.66
- ELEV 50.69
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.